JIPO: The Immune Checkpoint Inhibitors Journey: From Early Promise to Lasting Impact 2026
The target audience is oncologists, hematologists, medical specialists, primary care physicians, and healthcare professionals.
Course Director
Overview
This journal-based CME activity is built on the landmark JIPO review of immune checkpoint inhibitors. Read the accreditation and disclosure information, read the full article, then complete the evaluation to claim 1.0 AMA PRA Category 1 Credit. Original release 9/29/2026; expires 9/29/2027.
Hajjar J, Stephen B, Aaroe AE, et al. The immune checkpoint inhibitors journey: from early promise to lasting impact. J Immunother Precis Oncol. 2026;9. DOI: 10.36401/JIPO-26-12.
Learning Objectives
- Describe how to diagnose immunotherapy side effects early and accurately
- Explain the management approach to various immunotherapy side effects
Getting Started
To access InnoScholar courses, a membership plan is required. Login or sign up at innoscholar.com/join.
If you are enrolled in the course, then the course material is accessible below and through your Learner Dashboard.
At the end of each course, you’ll take a short quiz to reinforce the lesson(s). All digital badges and certificates you earn will be added to your dashboard!
Free Learning Material
The course is freely available.
Explore More Courses
Need help with your account or a course? Email learning@innoscholar.com and we will get back to you within 1 business day.
